The effectiveness of essential oils in the treatment of acute viral rhinosinusitis

Introduction. Acute respiratory viral infections are the most widespread diseases, accounting for up to 90% of all infectious pathology, which supports the relevance of optimizing the treatment of acute viral rhinosinusitis.
Aim. Evaluate the dynamics of clinical symptoms of acute viral rhinosinusitis, which arose as part of an acute respiratory infection, when supplementing therapy with the drug Respero Myrtol (Pol-Boskamp GmbH and Co.KG, Germany), the active ingredient of which is myrtol standardized 120 mg in 1 capsule.
Materials and methods. The dynamics of clinical symptoms of 20 cases of acute viral rhinosinusitis in comparison groups was analyzed. Traditional treatment of patients included taking propionic acid derivatives, ascorbic acid, intranasal use of decongestants and irrigation of the nasal cavity with isotonic saline solutions. Patients who have received traditional treatment are defined as a “standard therapy group”. To assess the effectiveness of therapy using standardized myrtol, 20 cases of acute viral rhinosinusitis against the background of acute respiratory viral infections with a similar severity were analyzed, in which patients received outpatient therapy with Respero Myrtol 2 capsules 3 times a day for 7 days in addition to the above treatment (the “myrtol therapy” group). The dynamics of the disease assessed: the number of days of disability before recovery, the period of normalization of body temperature in feverish patients, the need for vasoconstrictive intranasal agents after the seventh day of therapy, the period of complete relief of pain syndrome, the period of normalization of night sleep, the number of cases of bacterial superinfection and the need for systemic antibacterial therapy.
The results. In the observed patients, the quality of sleep was restored faster, the pain syndrome was stopped earlier, less often there was a need for systemic antibiotics and prolonged use of intranasal decongestants. The disease proceeded with fewer days of disability.
Conclusion. The study results have been shown to report the clinical efficacy of Respero Myrtol essential oils in the outpatient treatment of patients with acute rhinosinusitis.

1. Piskunov G.Z., Piskunov S.Z. Inflammation of the mucous membrane. Moscow: Kolos; 2008. 34 p. (In Russ).

2. Artushkin S.A., Ryazantsev S.V., Eremina N.V., Eremin S.A. Modern herbal medicines in the treatment of acute rhinosinusitis. Meditsinskiy Sovet. 2018;8:98–102. (In Russ.) https://doi.org/10.21518/2079-701X-2018-8-98-102.

3. Bezshapochny S.B., Grishina I.S. Treatment of acute rhinosinusitis with the use of modern secretolytics with proven clinical efficacy. Otorhinolaryngology. Eastern Europe. 2016;(4):614–619. (In Russ.) Available at: https://www.elibrary.ru/contents.asp?id=34336535.

4. Riazantsev S.V., Konoplev O.I., Sapova K.I. Mycolytic therapy of sinusitis. Vestnik Oto-Rino-Laringologii. 2014;(6):61–63. (In Russ.) https://doi.org/10.17116/otorino2014661-63.

5. Karpova E.P., Tulupov D.A. The possibilities of phytotherapeutic drugs based on myrtol standardized in the treatment of rhinosinusitis. RMJ. 2014;22(26):1912–1915. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Vozmoghnosti_fitoterapevticheskih_lekarstvennyh_sredstv_na_osnove_mirtola_standartizirovannogo_v_terapii_rinosinusita.

6. Lopatin A.S. Pharmacotherapy of inflammatory diseases of the paranasal sinuses. RMJ. 2000;(5):223. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Farmakoterapiya_vospalitelynyh_zabolevaniy_okolonosovyh_pazuh.

7. Svistushkin V.M., Nikiforova G.N., Merkushinа A.V., Dedova M.G. The use of herbal remedies in the prevention and treatment of pathology of the respiratory tract. Meditsinskiy Sovet. 2019;(12):64–69. (In Russ.) https://doi.org/10.21518/2079-701X-2019-12-64-69.

8. Rozhdestvensky D.A. Clinical pharmacology of medicines based on essential oils. Meditsinskie Novosti. 2015;(10):16–18. (In Russ.) Available at: https://www.mednovosti.by/journal.aspx?article=7220.

9. Lai Y., Dilidauer D., Chen B., Xu G., Shi J., Lee R.J. et al. In vitro studies of a distillate of rectifi ed essential oils on sinonasal components of mucociliary clearance. Am J Rhinol. 2014;28(3):244–248. https://doi.org/10.2500/ajra.2014.28.4036.

10. Schaller M. Preparation GeloMirtol® forte. Recipe. 2008;(1):107–108. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=19549334.

11. Han D., Wang N., Zhang L. The effect of myrtol standardized on human nasal ciliary beat frequency and mucociliary transport time. Am J Rhinol Allergy. 2009;23(6):610–614. https://doi.org/10.2500/ajra.2009.23.3401.

12. Grassmann J., Hippeli S., Dornisch K., Rohnert U., Beuscher N., Elstner E.F. Antioxidant properties of essential oils. Possible explanations for their anti-inflammatory effects. Arzneimittelforschung. 2000;50(2):135–139. Available at: https://pubmed.ncbi.nlm.nih.gov/10719616.

13. Hipelli S., Grassman J., Dornisch K., Rohnert U., Elstner E.F. Freie Radikale in Pathogenese und Therapie von entzundlichen Erkrankungen des Bronchialsystems In: Meister R. (ed.). Entzündliche Erkrankungen des Bronchialsystems. Springer-Verlag Berlin Heidelberg; 2000. https://doi.org/10.1007/978-3-642-59770-1_1.

14. Beuscher N., Kietzmann M., Bien E., Champeroux P. Interference of myrtol standardized with inflammatory and allergic mediators. Arzneimittelforschung. 1998;48(10):985–989. Available at: https://pubmed.ncbi.nlm.nih.gov/9825115.

15. Zimmermann T., Seiberling M., Thomann P., Karabelnik D. The relative bioavailability and pharmacokinetics of standardized myrtol. Arzneimittelforschung. 1995;45(11):1198–1201. (In German.) Available at: https://pubmed.ncbi.nlm.nih.gov/8929239.

16. Shchenikova E.Y. The possibilities of Gelomirtol in the treatment of acute and chronic inflammation of the respiratory system. Rossiiskaya Otorinolaringologiya. 2006;(3):86–89. (In Russ.) Available at: https://elibrary.ru/item.asp?id=9215353.

17. Rybak R.F. Experience in the use of Gelomirtol in the complex therapy of acute and chronic sinusitis. Recipe. 2009;(3):47–50. (In Russ.) Available at: https://www.plaintest.com/pharmaceutical/gelomirtol.

18. Karpova E.P., Emelyanova M.P., Tulupov D.A. Standardized phytopreparations in the treatment of acute rhinosinusitis in children. Pediatriya – Zhurnal im G.N. Speranskogo. 2016;95(1):97–102. (In Russ.) Available at: https://pediatriajournal.ru/archive?show=350&section=4535.

19. Bakhert K. Review of the experience of using herbal preparations for the treatment of acute rhinosinusitis from the standpoint of evidence-based medicine. Consilium Medicum. 2021;23(9):430–440. (In Russ.) Available at: https://cyberleninka.ru/article/n/obzor-opyta-primeneniya-rastitelnyhpreparatov-dlya-lecheniya-ostrogo-rinosinusita-s-pozitsii-dokazatelnoymeditsiny.

20. Federspil P., Wulkow R., Zimmermann T. Effects of standardized Myrtol in therapy of acute sinusitis-results of a double-blind, randomized multicenter study compared with placebo. Laryngorhinootologie. 1997;76(1):23–27. (In German.) https://doi.org/10.1055/s-2007-997381.

21. Ovchinnikov A.Yu., Panyakina M.A., Protsenko E.O., Korostelev S.A. The effectiveness of Gelomirtol Forte in the treatment of patients with acute rhinosinusitis. Farmateka. 2014;(15):35–39. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/30187.

22. Grishchenko E.B. Gelomirtol forte is a natural mucosecretolytic with proven clinical efficacy. Consilium Medicum. Pulʹmonologiya. 2010;(1):37–41. (In Russ.) Available at: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2010/pulmo2010_pril/gelomirtol-forte-naturalnyymukosekretolitik-s-dokazannoy-klinicheskoy-effektivnostyu.

23. Magomedov A.Z., Kudaev M.T., Akhmedova D.A., Ataeva Z.N., Osmanova A.V., Huseynova R.K., Kallaeva A.N. Efficacy of gelomirtol forte therapy in exacerbation of chronic obstructive pulmonary disease. In: Chuchalin A.G. (ed.). Man and Medicine. Abstracts of the XXIII Russian National Congress. Ser. “Library of the Russian National Congress “Man and Medicine”. Moscow, April 11–14, 2016. Moscow; 2016, pp. 147–154. (In Russ.) Available at: https://elibrary.ru/item.asp?id=41539601&pff=1.

24. Ovchinnikov A.Yu., Eje M.A., Khon E.M., Korostelev S.A. Acute rhinosinusitis: basic misconceptions and possibilities of standardized phytotherapy. Meditsinskiy Sovet. 2016;(6):28–31. (In Russ.) https://doi.org/10.21518/2079-701X-2016-6-28-31.

25. Kunelskaya N.L., Turovsky A.B., Zarapkin G.Yu., Kolbanova I.G., Izotova G.N. Mucolytic therapy of acute and chronic rhinosinusitis. Meditsinskiy Sovet. 2015;(3):12–17. (In Russ.) Available at: https://www.med-sovet.pro/jour/article/view/129/129.

26. Shostak N.A., Kryukov A.I., Kunelskaya N.L., Turovsky A.B. Mucolytic therapy for respiratory diseases: research continues. Meditsinskiy Sovet. 2013;(11):88–92. (In Russ.) Available at: https://www.med-sovet.pro/jour/article/view/1153/1133.

27. Ryazantsev S.V. Mucoactive therapy in the complex treatment of acute and chronic sinusitis. Recipe. 2007;(3):138–142. (In Russ.) Available at: https://elibrary.ru/qyppop.

28. Zakharova G.P. The effectiveness of using a combination of mucoactive therapy and local corticosteroids in the complex treatment of patients with chronic rhinosinusitis. Rossiiskaya Otorinolaringologiya. 2006;(6):72–76. (In Russ.) Available at: https://elibrary.ru/item.asp?id=9298478.

29. Lavrenova G.V., Glukhova E.Yu., Mongush S.L., Shishkunova T.M., Mitina A.O., Tarasova M.A. Phytotherapy in the complex treatment of viral inflammation of ENT organs. In: Blotsky A.A. (ed.). Materials of the interregional scientific and practical conference of otorhinolaryngologists of Siberia and the Far East with international participation “Topical issues of otorhinolaryngology”. Blagoveshchensk, June 30, 2016. Blagoveshchensk; 2016, pp. 5–11. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=26282401.